30 November 2023



Meet GSK management Getting ahead of respiratory diseases Interactive event for investors and analysts. This webinar is being recorded.

Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for the full year (FY) 2022. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q3 2023 earnings release and Annual Report on Form 20-F for FY 2022.

All guidance, outlooks, ambitions and expectations should be read together with the guidance, assumptions and cautionary statement in the Q3 2023 earnings release and the 2022 Annual Report.

Basis of preparation: On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.

Today's speakers




Dr Tony Wood Chief Scientific Officer



Luke Miels Chief Commercial Officer

GSK prevents and treats disease in four core therapy areas



Enabled by advanced technology and data platforms with targeted business development

Today's focus

- Our expertise in Respiratory
- Our treatment approach from symptom control to disease modification
- The importance and updated potential of IL-5, Nucala and depemokimab
- Market potential of Refractory Chronic Cough (RCC) and camlipixant's differentiation
- Key respiratory data readouts 2024-2026+

Leader in respiratory prevention and treatment for decades

Best-in-class vaccines and medicines; innovative and easy-to-use devices

Innovator of small molecules in easy-to-use devices

- 1969: *Ventolin*: 1st selective SABA¹ for asthma
- 1998: Seretide/Advair. 1st ICS/LABA² combination for asthma
- 2013: Anoro: 1st LABA/LAMA³ for COPD⁴
- 2017: *Trelegy*: 1st single once-daily ICS/LABA/LAMA combination inhaler launched for COPD

Best-in-class biologic reducing need for oral steroids

Nucala: 1st mAb⁵ that targets $IL-5^{\circ}$ for

- 2015: severe asthma
- 2017: eosinophilic granulomatosis with polyangiitis (EGPA)
- 2020: hypereosinophilic syndrome (HES)
- 2021: chronic rhinosinusitis with nasal polyps (CRwNP)

Leader in seasonal respiratory infection

- Arexvy: 1st for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus
- *Fluarix*: influenza can result in serious complications, hospitalisation, and death
- COVID-19: a neutralising monoclonal antibody used to treat COVID-19

Next-wave of treatment innovation and long-acting options

- Nucala (lifecycle innovation): 1st mAb that targets IL-5 for COPD
- **depemokimab:** 1st longacting mAb that targets IL-5 for severe asthma
- depemokimab (lifecycle innovation): 1st long-acting mAb that targets IL-5 for EGPA, HES, CRwNP
- **camlipixant**: best-in-disease P2X3 for refractory chronic cough

6


Delivering competitive growth at scale

Respiratory medicines and vaccines ~38% of 2022 sales

Sales from respiratory vaccines and medicines^{1,2}

£11bn

+8% CAGR³




Trelegy sales¹


£1.7bn

+32% CER⁴

Nucala sales¹

£1.4bn +18% CER⁴





1. Full-year 2022 sales 2. Includes *Trelegy, Nucala, Anoro, Arnuity, Incruse, Revlar/ Breo, Avamys/ Veramyst, Flixodite/ Flovent, Seretide/ Advair, Ventolin, Respiratory Other, COVID-19, and Fluarix* 3. Compound annual growth rate 2016 to 2022 based on reported sales 4. Full-year 22 sales growth at constant exchange rates

To treat respiratory disease remains an area of high unmet need A significant and growing burden to patients and society

Asthma

~315 million

individuals suffering from asthma worldwide 50-70% have eosinophilic asthma¹

Market opportunity: £11bn by 2030²

Chronic rhinosinusitis with nasal polyps

>0.5 million

diagnosed cases in the US 90% of recurrent patients have an eosinophilic phenotype³

Market opportunity: £2bn by 2030²

Chronic obstructive pulmonary disease

~212 million

individuals suffering from COPD worldwide 37% have an eosinophilic phenotype

Market opportunity: £4bn by 2030²

Refractory chronic cough

~28 million

individuals diagnosed worldwide ~10 million individuals with RCC >1 year⁴

Market opportunity: £4bn by 2030²

Advancing treatment goals to clinical remission

Ambition to prevent and treat respiratory diseases by reducing signs and symptoms, addressing treatment resistance and slowing disease progression

Example: clinical remission in asthma



Past Bronchodilation and symptom control



Present

Exacerbation reduction



Tomorrow

Clinical remission


Four components of clinical remission

- Exacerbation free
- OCS free
- Symptom control
- Stabilised lung function



Future

Clinical remission leading to disease modification



Aspiring to achieve clinical remission in specific types of severe asthma




Understanding the biological effects of IL-5

IL-5 plays a broad role beyond eosinophilic inflammation

11

Eosinophils and IL-5 play a central role in controlling inflammation and its healthy resolution Eosinophils are a key driver of T2 inflammation; IL-5 is a key cytokine for type 2 processes




Nucala sustained clinical remission in real-world evidence studies Comprehensive clinical programme to generate evidence

REALITI-A

37%

Demonstrated that 37% of patients achieved fourcomponent clinical remission at 104 weeks assessed in post-hoc analysis in patients with severe asthma^{*,1} Forthcoming prospective studies examining clinical remission



GSK ^{*}

* REALITI-A -At Week 52 29% (n=61/214) of patients achieved 3-Component Clinical Remission compared with 2% (n=4/214) of patients at baseline. At Week 52 35% (n=26/74) of patients achieved 4-Component Clinical Remission compared with 4% (n=3/74) of patients at baseline 1. Brusselle G, et al. ATS 2023; #P203; 2. Chupp G, et al. AAAAI 2023; #P60; 3. Bagnasco D, et al. ERS 2023; #PA630; 4. Pilette C, et al. J Allergy Clin Immunol Pract 2022;10:2646–2656; 5. Domingo Ribas C, et al. Drugs 2021;81:1763–1774; 6. Domingo Ribas C, et al. ATS 2022; #P606; 7. Domingo Ribas C, et al. ERS 2022; #P1344; 8. Pavord I, et al. Front Immunol 2023;14:1120162; 9. Oppenheimer J, et al. ERS 2023; #PA646; 10. https://classic.clinicaltrials.gov/ct2/show/NCT06041386?term=reimagine&cond=asthma&draw=2&rank=1,

Leading the science in COPD with an eosinophilic phenotype MATINEE redesign increases chances of success for depemokimab COPD trials

Nucala's METREX/METREO phase III trials helped inform future development

- Provided first demonstration of efficacy with a biologic in COPD
- The risk of moderate/severe exacerbations reduced by 24% in patients stratified by blood eosinophils ≥300 cells/µL

MATINEE phase III patient population

• Stricter eosinophil entry criteria with elevated eosinophil counts

• No history of asthma

 Studying a broad population of chronic bronchitis and emphysema

H2 2024: MATINEE phase III data readout (COPD)


Depemokimab

Potential best-in-class next-generation IL-5 treatment for eosinophilic-led disease

Depemokimab: next generation IL-5 enabling twice-yearly dosing Development acceleration delivers lifecycle innovation in two versus seven years

Enhanced binding and longer half-life enable less frequent dosing

- Progressed directly from phase I to III based on published PK/PD modelling of eosinophil reduction
- Engineered specifically for higher potency, longer binding affinity, and improved dosing interval



Adjusted geometric mean ratio to baseline blood eosinophil count¹

Four indications in simultaneous phase III clinical development

H1 2024

SWIFT 1 and SWIFT 2 Phase III data readout (asthma)

H2 2024


ANCHOR 1 and ANCHOR 2 Phase III data readout (CRSwNP²)

2025+


NIMBLE Phase III data readout (asthma)

OCEAN Phase III data readout (EGPA³)


DESTINY Phase III data readout (HES⁴)




High economic burden and a clear unmet medical need Increased biologic use in respiratory will drive further market expansion







Depemokimab: improved real-world efficacy with improved dosing Providing benefits for patients, payers and physicians



Expected benefits of depemokimab will drive biologics growth

Efficacy

- Improved real-world efficacy outcomes
- First clinical studies to include clinical remission prospective outcomes

Real World Experience

- Analogues show that 6m dosing improves compliance²
- Autoimmune diseases analogues suggest +25% in adherence³
- Other long-term condition analogues suggest +37% increase in persistency⁴

Patient Benefit³

- Reduced HCP visits from up to 12 to 2 per year⁵
- Reduced patient burden and impact on lifestyle with fewer injections
- Low co-pay burden for majority of patients

Payer Administration⁴

- Less wastage from patient mishandling and shipment
- Reduced reimbursement administration burden for HCPs⁷ and patients through Part B

GSK

I. Bio-penetration defined as the % of eligible patients currently receiving a biologic therapy 2. Syneos health New Product Planning Flex Resourcing Support 3. Adherence: the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen 4., Persisence: the duration of time from initiation to discontinuation of therapy 5. IQVIA PMR 6. Estimated OOP costs based on Payer Mix, IQVIA Nucala Claims snapshot 7. Healthcare profeessionals

Focused development to drive breadth of indications in two years

Indication	Nucala	depemokimab	benralizumab	tezepelumab	dupilumab
Severe eosinophilic asthma	\checkmark	Phase III			
CRSwNP ¹	\checkmark	Phase III	2025	2025	\checkmark
EGPA	~	Phase III	2024		
HES	~	Phase III	2025		
COPD	Phase III	Investment decision pending	2026	2028	2024
				~	GSK has launched

GSX 1. Differences in CRWwNP data; pre-surgery: dupilumab, tezepelumab, depemokimab; post-surgery: Nucala, benralizumab, tezepelumab, depemokimab,

Competitor has launched \checkmark Anticipated launch YEAR

19

Depemokimab: high HCP willingness to prescribe, strong patient preference

Physician Belief

73% physicians believe a 6-month biologic for asthma would be highly 'beneficial'

Physician Prescribing 57% of HCPs would consider prescribing dependentiation of HCPs would consider switching patients from current treatment to dependentiation

Patient Preference

6 out of 10 patients say a 6-monthly injection would make it easier to manage their asthma³ 87% of patients state they would be very/fairly likely to use depemokimab if supported by an HCP⁴



. Research Partnership Quant uptake MR, 200 US HCPs. Top two box on a seven-point scale where seven equalled "highly beneficial" 2. Adelphi conjoint 3. Pollfish survey, 100 US patients 4. 65pts Health Hub Voice


Depemokimab share will come from all biologics¹ Source of business

HCPs believe that depemokimab would expand bio-penetration

Eligible patients

20%

who don't get a biologic today would be prescribed one if depemokimab were available²



Depemokimab: increased sales potential from £1-2 billion Upgrading sales expectations

depemokimab

>£3bn

in peak year sales¹


- Accelerated lifecycle innovation includes potential launches for four indications between 2026 and 2027
- Twice-yearly dosing leads to increased bio-penetration and market expansion
- 2/3rds sales contribution by 2031

IL-5 medicines

>£4bn


in total sales²

• Nucala COPD to offset base decline




Camlipixant

Potential best-in-disease P2X3 antagonist in phase III development for treatment of refractory chronic cough




Refractory chronic cough patients often experience an emotionally taxing and lengthy journey as they seek to resolve their cough

Refractory chronic cough is a distinct neuropathic disorder Highly prevalent causing misery, pain, exhaustion, isolation



Patients have few effective treatments; no licensed targeted therapies* Cycle through multiple treatments and physicians without resolution



*Competing P2X2/3 is licensed in Switzerland and Japan 1. US RCC Market Opportunity Findings; N=661 HCPs; ZS Associates 2. Morice AH, Millqvist, E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Zacharasiewicz, A. Eur Respir J. 2020, 55(1). 3. Gibson P, Wang G, McGarvey L, Vertigan AE, Altman KW, Birring SS, Panel CEC. Chest 2016, 149(1), 27-44 4, US RCC Patient Journey Quant Research, N=201 Patients, Advanced Marketing and Insights, 2022

Refractory chronic cough: high burden, low treatment satisfaction HCP's have a high willingness to prescribe innovative treatments

No standard of care, options today are poor¹




3%

Specialists say RCC is extremely burdensome

Low HCP satisfaction rate for current RCC treatments Willingness to try new therapies is high across all stakeholders

Assuming no safety concerns, I will definitely try a new treatment or approach if I believe my Refractory Chronic Cough (RCC) patients may benefit from it, even if I am not fully familiar with it¹


% Agree or Strongly Agree




Camlipixant: potential best-in-disease medicine for RCC High selectivity for P2X3 drives efficacy with fewer off-target effects

P2X3 selectivity provides potential efficacy & tolerability benefits

- Minimising the urge to cough by antagonising the P2X3 receptor & stopping hypersensitisation¹²
- Highest selectivity for P2X3 leading to potential efficacy benefit & best-in-class tolerability³
- Off-target activity of competitor P2X2/3 heterotrimer causes issues with taste disturbance^{4,5,6}



SOOTHE phase IIb trial demonstrated 34% placebo-adjusted reduction from baseline in 24-hour cough frequency⁷



SOOTHE phase IIb trial demonstrated very low taste related adverse events⁸ 6.5% Rate of taste-related adverse events

0%

0% Taste-related discontinuations

0% 50% 100%

50%

100%

GSK

1.Mazzone et al. (2016) Physiol Rev. 96(3):975-1024. ,2. Abdulqawi (2015) 385(9974):1198-205 3. Garceau et al. (2019) Pulm Pharmacol Ther 56:56-62. 4. Finger (2005) Science 310(5753):1495-9., 5 .Abdulqawi (2015) 385(9974):1198-205 6. Garceau et al. (2019) Pulm Pharmacol Ther 56:56-62. 7. Smith et al. Am J Respir Crit Care Med 2022;205:A5778 8. US RCC Rapid Quant Survey, N=120 HCPs (PULMS, ENTs and ALG), 2023


Camlipixant: phase III CALM programme, data expected in H2 2025 Optimised study design ensures placebo effect and baseline characteristics

Study population and primary endpoint


- Refractory/unexplained chronic cough; Cough ≥1 year
- CALM-1 and CALM-2: 825 participants per study
- Endpoints:- 24H cough frequency (CF) at 12-weeks (CALM-1) and 24-weeks (CALM-2)

Important phase III elements

- Patient enrichment with higher baseline cough frequency should likely reduce placebo effect
- Taste-related adverse events is low due to high selectivity, reducing risk of unblinding
- Engaged with US FDA regarding patient-reported outcomes



CALM-2



CALM-1 Study. Clinicaltrials.gov [cited 14NOV2023] accessed from: https://www.clinicaltrials.gov/study/NCT05599191?cond=chronic%20cough&intr=BLU-5937&rank=2 CALM-2 Study. Clinicaltrials.gov [cited 14NOV2023] accessed from: https://www.clinicaltrials.gov/study/NCT05599191?cond=chronic%20cough&intr=BLU-5937&rank=2 CALM-2 Study. Clinicaltrials.gov [cited 14NOV2023] accessed from: https://www.clinicaltrials.gov/study/NCT05509191?cond=chronic%20cough&intr=BLU-5937&rank=3

Camlipixant: strong physician preference versus competition >£2.5bn PYS driven by leading class share in a large market with high unmet need

Taste disturbance is a significant issue for competitor both in clinical studies and in real world

Competitor P2X2/3 Clinical Studies¹

0%	50%	100%
	0%	0% 50%

14%

Taste-related

discontinuations

0% 50%

100%

Competitor P2X2/3 Japanese Real-World Experience²

Dysgeusia is a frequent issue with gefapixant, causing ~20% of patients to discontinue

54 st a ge

54% of Japanese HCPs state "taste disturbance" as a barrier to prescribing gefapixent Strong HCP preference for camlipixant profile versus competitor³

73% believe camlipixant to be best-in-class in Refractory Chronic Cough

85% prefer camlipixant based on "low incidence of taste-related adverse effects (i.e. taste disturbances / complete or partial taste loss)"



1. McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. Lancet. 2022 Mar 5;399(10328):909-923. 2. Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, Nguyen AM, Schelfhout J, Li Q, Iskold B, Green SA, Philip G, Muccino DR, and Rosa CL. Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. 3. IQVIA Market Landscape & Opportunity Assessment in Japan. October 2022, n=201.4. US RCC Rapid Quant Survey, N=120 HCPs (PULMS, ENTs and ALG), 2023

Respiratory medicines growth drivers

Nucala (COPD) ~£0.5-1bn

in peak sales¹

depemokimab

>£3bn

in peak year sales¹

camlipixant

>£2.5bn

in peak year sales¹

- Despite triple therapy utilisation 40% of total COPD patients still exacerbate
- 37% of COPD patients have an eosinophilic phenotype
- 400k eligible population (US)
- Only 28% of eligible US patients currently receive a biologic
- 57% of physicians likely to prescribe depemokimab in bio naïve patients
- 66% likely to switch a patient from their current biologic to long acting
- 87% of patients would likely use based on physicians' recommendation
- High prevalence: 28m patients globally significant burden and unmet medical need
- ~70% of HCPs willing to try a new treatment
- ³/₄ of HCPs expect camlipixant to be best-indisease
- 85% prefer camlipixant due to low taste impact

GSK

Forthcoming catalysts

	H1 2024	H2 2024	2025	2026+
Nucala		MATINEE Phase III data readout (COPD)		
		Regulatory decisions Japan (CRSwNP) China (severe asthma)		
depemokimab	SWIFT 1 and SWIFT 2 Phase III data readout (asthma)	ANCHOR 1 and ANCHOR 2 Phase III data readout (CRSwNP)	NIMBLE Phase III data readout (asthma) OCEAN Phase III data readout (EGPA)	DESTINY Phase III data readout (HES)
camlipixant			CALM 1 and CALM 2 Phase III data readout	
55K 1. Non-risk adjusted peak year	sales potential is subject to certain assumptions	consistent with those for previous outlooks, amb	itions and expectations	



Use of GSK conference call, webcast and presentation slides

The GSK plc webcast, conference call and presentation slides (together the 'GSK materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the GSK materials in any way. You may not edit, alter, adapt or add to the GSK materials in any way, nor combine the GSK materials with any other material. You may not download or use the GSK materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the GSK materials. You may not use the GSK materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. GSK plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Telephone +44 20 8047 5000, www.gsk.com

GSK